Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells-Reference-Cited by-同舟云学术

Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells

Published:2021-01-05 Issue:1 Volume:17 Page:266-274
ISSN:1734-1922
Container-title:Archives of Medical Science
language:
Short-container-title:Arch Med Sci

Author:

Regev Ofer¹²,Kidan Noa¹³,Nicola Meshel¹²,Khamisie Hazem¹,Ruthardt Martin⁴,Mahajna Jamal¹²

Affiliation:

1. Department of Nutrition and Natural Products, Migal-Galilee Research Institute, Kiryat Shmona, Israel

2. Department of Biotechnology, Tel Hai College, Kiryat Shmona, Israel

3. Department of Nutritional Sciences, Tel Hai College, Kiryat Shmona, Israel

4. Department of Hematology, Division of Cancer and Genetics, and Experimental Clinical Medical Center (ECMC), Medical School, Cardiff University, Cardiff, United Kingdom

Publisher

Termedia Sp. z.o.o.

Subject

General Medicine

Link

https://www.archivesofmedicalscience.com/pdf-127894-60738

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming Chemoresistance in Cancer: The Promise of Crizotinib;Cancers;2024-07-07

2. Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells;Translational Oncology;2024-06

3. Ascites in malignant ovarian cancer confer ovarian cancer cells chemoresistance to platinum. Combination treatment with crizotinib and 2-hydroxyestradiol restores platinum sensitivity;2023-09-24

4. Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells;International Journal of Molecular Sciences;2023-04-23

5. Secreted soluble factors from tumor-activated mesenchymal stromal cells confer platinum chemoresistance to ovarian cancer cells;2023-02-26